Search by Drug Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for IXABEPILONE
- Anti-tumor Effect of Ixabepilone in Metastatic Breast Cancer (mBC) Selected by the Ixabepilone DRP.
- Evaluation of Weekly Ixabepilone With or Without Biweekly Bevacizumab
- A Study of Etirinotecan Pegol (NKTR-102) Versus Treatment of Physician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline, a Taxane, and Capecitabine
- Eribulin Plus Gemcitabine (EG) vs Paclitaxel Plus Gemcitabine (PG) in HER2-Negative Metastatic Breast Cancer
- PREDATOR: Neoadjuvant Gene Prediction for Breast Cancer
- Ixabepilone and SBRT For Metastatic Breast Cancer
- Study of Chemotherapy in Combination With IDO Inhibitor in Metastatic Breast Cancer
- The Purpose of This Study is to Determine if Tetrodotoxin (TTX) is Effective in the Treatment of Pain Resulting From Chemotherapy Treatment
- A Phase I Study of Lapatinib (Tykerb) Plus Ixabepilone (Ixempra) as 2nd-line Treatment for Patients With HER-2 Overexpressed Recurrent or Persistent Endometrial Carcinoma or Carcinosarcoma
- Chloroquine With Taxane Chemotherapy for Advanced or Metastatic Breast Cancer After Anthracycline Failure (CAT)
- A Study of LY2523355 in Participants With Breast Cancer
- Ixabepilone and Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
- Investigational Drug in Combination With Two Chemotherapy Drugs in Women With Locally Recurrent or Metastatic Breast Cancer
- Ixabepilone in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Previously Treated With Chemotherapy
- Ixabepilone and Pemetrexed/Solid Tumors
- Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
- Neo-Adjuvant Study in Triple Negative Breast Cancer Patients
- Ixabepilone and Vorinostat in Treating Patients With Metastatic Breast Cancer
- Radiation Therapy and Ixabepilone in Treating Patients With High-Risk Stage III Prostate Cancer After Surgery
- Ixabepilone + Carboplatin Metastatic Breast Cancer
- Trial of Bevacizumab and Ixabepilone for Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)
- A Rollover Study of Ixabepilone (BMS-247550) In Patients With Metastatic Breast Cancer Previously Treated With An Anthracycline
- Clinical Study of Ixabepilone (BMS-247550) by Every-3-week Dosing Regimen in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and Who Are Taxane Resistant
- Study of Ixabepilone (BMS-247550) in Patients With Solid Tumors
- Study of Pazopanib and Ixabepilone in Patients With Solid Tumors
- Calcium and Magnesium in Preventing Peripheral Neuropathy Caused by Ixabepilone in Patients With Breast Cancer
- Carboplatin, Ixabepilone, and Cetuximab in Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Untreated With Chemotherapy
- Study of Ixabepilone in Asian Subjects With Unresectable or Metastatic Gastric Cancer
- Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer
- Trial of Dasatinib Plus Ixabepilone in 2nd or 3rd Line Metastatic Breast Cancer
- Ixabepilone to Treat Cervical Cancer
- Bevacizumab Plus Ixabepilone to Treat Patients With Advanced Kidney Cancer
- Ixabepilone and Sunitinib Malate in Treating Patients With Progressive Advanced Solid Tumors
- A Study of Ixabepilone as Second-line Therapy for Locally Advanced, Recurrent, or Metastatic Endometrial Cancer
- A Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Patients With Advanced Breast Cancer
- Ixabepilone in Treating Participants With Significant Residual Disease of HER2/Neu Negative Invasive Breast Cancer After Systemic Therapy
- Ixabepilone and Cyclophosphamide as Neoadjuvant Therapy in HER-2 Negative Breast Cancer
- Phase I Combination Ixabepilone + Cisplatin
- Neoadjuvant Weekly Ixabepilone for High Risk, Clinically Localized Prostate Cancer
- Phase I/II Trial of Sorafenib Plus Ixabepilone in HER2-Negative Metastatic Breast Cancer
- Neoadjuvant Ixabepilone/Carboplatin/Trastuzumab in HER2-Positive Locally Advanced Breast Cancer
- Lapatinib and Ixabepilone in Treating Patients With Advanced Solid Tumors
- Ascending Multiple-Dose Study of Brivanib Alaninate in Combination With Chemotherapeutic Agents in Subjects With Advanced Cancers
- Trial of Ixabepilone in Patients With HER-2 Negative Metastatic Breast Cancer (HIT)
- A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast Cancer
- Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer
- Ixabepilone and Hydroxychloroquine in Treating Patients With Metastatic Breast Cancer
- FEC With G-CSF Support Followed by Ixabepilone With G-CSF Support as Neoadjuvant Chemotherapy in BC
- Ixabepilone and Carboplatin +/- Bevacizumab in Advanced Non-Small-Cell Lung Cancer
- A Randomized Phase 2 Study of Ixabepilone Plus Carboplatin and Paclitaxel Plus Carboplatin in Advanced Nonsmall-Cell Lung Cancer
- Solid Tumors Using Ixabepilone and Dasatinib
- Ixabepilone in Combination With Carboplatin in Patients With Non-small Cell Lung Cancer
- A Study of Ixabepilone Before Surgery for High-Risk Localized Prostate Cancer
- Paricalcitol and Chemotherapy in Treating Women With Metastatic Breast Cancer
- Phase I Study of Ixabepilone Plus Lapatinib With or Without Capecitabine in the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer
- Randomized Phase II Study of Ixabepilone Alone and Ixabepilone Plus Cetuximab as First-Line Treatment for Female Subjects With Triple Negative Locally Advanced Non-resectable and/or Metastatic Breast Cancer
- Phase 1 Trial of Oral Ixabepilone
- Safety and Efficacy Comparison of Docetaxel and Ixabepilone in Non Metastatic Poor Prognosis Breast Cancer
- Phase II Study of Ixabepilone in Metastatic Breast Cancer and Its Effects on the Ultrastructure of Neurons
- Phase II Trial of Weekly or Every 3-week Ixabepilone for Patients With Metastatic Breast Cancer
- A Phase I Study of Ixabepilone in Combination With Capecitabine in Japanese Patients With Metastatic Breast Cancer
- Randomized Study Evaluating Ixabepilone Plus Capecitabine or Docetaxel Plus Capecitabine in Metastatic Breast Cancer
- A Phase II Combination of Trastuzumab and Ixabepilone Versus Trastuzumab and Docetaxel in Patients With Advanced and/or Metastatic Breast Cancer
- Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer
- A Phase I Study of Oral Ixabepilone in Subjects With Advanced Cancer
- A Phase II, Trial of Ixabepilone Plus Cetuximab as First Line Therapy for Metastatic Pancreatic Cancer
- A Trial of 2 Schedules of Ixabepilone Plus Bevacizumab and Paclitaxel Plus Bevacizumab for Breast Cancer
- A Study of the Alternative Administration of Ixabepilone and Vinflunine
- Ixabepilone in Treating Young Patients With Refractory Solid Tumors
- Treating Patients With Metastatic Prostate Cancer Not Responding to Hormone and Chemotherapy
- Phase I Combination w/ Epirubicin
- Ixabepilone Administered as an Enteric Coated Formulation.
- Effect of Capecitabine on the Pharmacokinetics of BMS-247550 and BMS-247550 on the Pharmacokinetics of Capecitabine and Its Metabolites in Patients With Advanced Malignancies
- Effect of Rifampin on the Pharmacokinetics of Ixabepilone in Patients With Advanced Cancer
- Ixabepilone and Liposomal Doxorubicin in Advanced Ovarian Cancer
- Ixabepilone in Treating Patients With Metastatic, Recurrent, or Unresectable Kidney Cancer
- Clinical Study of Ixabepilone Administered as a 24 Hour Infusion in Patients With Solid Malignancies.
- Ixabepilone and Ketoconazole in Treating Patients With Advanced Solid Tumors
- Ixabepilone in Treating Patients With Recurrent or Persistent Endometrial Cancer
- Ixabepilone in Treating Patients With Metastatic Prostate Cancer
- Epothilone (Ixabepilone) Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer
- Novel Epothilone (BMS-247550) in Patients With Metastatic Breast Cancer (MBC)
- Trastuzumab and Ixabepilone in Treating Women With HER2-Positive Metastatic Breast Cancer
- Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With HER2/Neu-Positive Metastatic Breast Cancer
- Ixabepilone in Treating Patients With Advanced Cisplatin-Refractory Germ Cell Tumors
- Ixabepilone Compared With Mitoxantrone and Prednisone in Treating Patients With Refractory Metastatic Prostate Cancer
- Ixabepilone in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma
- BMS-247550 Plus Cisplatin in Treating Patients With Metastatic or Recurrent Head and Neck Cancer
- Ixabepilone in Treating Patients With Relapsed or Refractory Lymphoproliferative Disorders
- S0355 Ixabepilone in Treating Patients With Advanced Solid Tumors or Lymphomas and Liver Dysfunction
- BMS-247550 Plus Capecitabine in Treating Patients With Metastatic Breast Cancer
- A Phase I/II Trial of BMS-247550 for Treatment of Patients With Recurrent High-Grade Gliomas
- Ixabepilone in Treating Patients With Locally Advanced or Metastatic Breast Cancer
- BMS-247550 and Gemcitabine in Treating Patients With Advanced Solid Tumors
- BMS-247550 in Treating Patients With Stage IV Melanoma
- Ixabepilone in Treating Patients With Metastatic or Recurrent Squamous Cell Cancer of the Head and Neck
- BMS-247550 in Treating Patients With Metastatic Colorectal Cancer
- BMS 247550 to Treat Kidney Cancer
- Ixabepilone in Treating Patients With Relapsed and/or Refractory Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cancer
- Ixabepilone in Treating Young Patients With Solid Tumors or Leukemia That Haven't Responded to Therapy
- BMS-247550 Plus Carboplatin in Treating Patients With Recurrent or Refractory Solid Tumors
- Ixabepilone With or Without Estramustine in Treating Patients With Progressive Prostate Cancer
- Ixabepilone in Treating Patients With Ovarian Epithelial or Primary Peritoneal Cancer That Has Not Responded to Previous Chemotherapy
- BMS-247550 in Treating Patients With Liver or Gallbladder Cancer
- BMS-247550 in Treating Patients With Advanced Soft Tissue Sarcoma
- Ixabepilone in Treating Patients With Advanced Urinary Tract Cancer
- BMS-247550 in Treating Women With Metastatic Breast Cancer
- BMS-247550 in Treating Patients With Recurrent Metastatic Stomach Cancer That Has Been Previously Treated With Chemotherapy
- BMS-247550 in Treating Patients With Metastatic Stomach Cancer Previously Treated With Chemotherapy
- BMS-247550 in Treating Patients With Advanced Pancreatic Cancer
- BMS-247550 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy
- BMS-247550 in Treating Patients With Advanced Cancers
- Treating Patients With Advanced Solid Tumors, Breast Cancer or Recurrent Ovarian Cancer
- BMS-247550 in Treating Patients With Advanced Solid Tumors That Have Not Responded to Previous Therapy
Clinical trials list
click for details